Amylyx Pharmaceuticals Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
136
- Stock Symbol
-
AMLX
- Investments
-
1
- Share Price
-
$30.28
- (As of Friday Closing)
Amylyx Pharmaceuticals General Information
Description
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Contact Information
Website
www.amylyx.comCorporate Office
- 55 Cambridge Parkway
- Suite 6 West
- Cambridge, MA 02142
- United States
Corporate Office
- 55 Cambridge Parkway
- Suite 6 West
- Cambridge, MA 02142
- United States
Amylyx Pharmaceuticals Stock Performance
As of 13-Nov-2026, Amylyx Pharmaceuticals’s stock price is $30.28. Its current market cap is $3.89B with 129M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $30.28 | $29.86 | $10.83 - $41.14 | $3.89B | 129M | 2.13M | -$1.45 |
Amylyx Pharmaceuticals Financials Summary
As of 30-Sep-2026, Amylyx Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,406,925 | 988,565 | 27,283 | 643,584 |
| Revenue | 0 | 0 | 87,371 | 380,786 |
| EBITDA | (175,232) | (153,466) | (315,041) | 39,230 |
| Net Income | (163,195) | (144,735) | (301,743) | 49,271 |
| Total Assets | 786,795 | 332,645 | 193,634 | 517,454 |
| Total Debt | 4,943 | 5,957 | 1,981 | 4,237 |
Amylyx Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Amylyx Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Amylyx Pharmaceuticals Comparisons
Industry
Financing
Details
Amylyx Pharmaceuticals Competitors (9)
One of Amylyx Pharmaceuticals’s 9 competitors is Alnylam Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Biohaven | Formerly VC-backed | New Haven, CT | ||||
| Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA | ||||
| Aquinnah | Venture Capital-Backed | Cambridge, MA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY |
Amylyx Pharmaceuticals Patents
Amylyx Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026136695-A1 | Liver x receptor agonists, compositions and methods | Pending | 20-Dec-2024 | ||
| WO-2026122969-A1 | Chi3l1-targeting oligonucleotides and methods of using the same | Pending | 06-Dec-2024 | ||
| US-20260151460-A1 | Treatment of post-bariatric hypoglycemia | Pending | 02-Dec-2024 | ||
| WO-2026122473-A1 | Treatment of post-bariatric hypoglycemia | Pending | 02-Dec-2024 | ||
| WO-2026036030-A1 | Antisense oligonucleotides targeting calpain-2 | Pending | 09-Aug-2024 | C12N15/113 |
Amylyx Pharmaceuticals Signals
Amylyx Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Amylyx Pharmaceuticals Investments (1)
Amylyx Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Eiger BioPharmaceuticals (Patent Right of Avexitide) for . The deal was made on 09-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Eiger BioPharmaceuticals (Patent Right of Avexitide) | 09-Jul-2024 | Corporate Asset Purchase | Buildings and Property |
Amylyx Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.41 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Amylyx Pharmaceuticals FAQs
-
When was Amylyx Pharmaceuticals founded?
Amylyx Pharmaceuticals was founded in 2013.
-
Where is Amylyx Pharmaceuticals headquartered?
Amylyx Pharmaceuticals is headquartered in Cambridge, MA.
-
What is the size of Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals has 136 total employees.
-
What industry is Amylyx Pharmaceuticals in?
Amylyx Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Amylyx Pharmaceuticals a private or public company?
Amylyx Pharmaceuticals is a Public company.
-
What is Amylyx Pharmaceuticals’s stock symbol?
The ticker symbol for Amylyx Pharmaceuticals is AMLX.
-
What is the current stock price of Amylyx Pharmaceuticals?
As of 13-Nov-2026 the stock price of Amylyx Pharmaceuticals is $30.28.
-
What is the current market cap of Amylyx Pharmaceuticals?
The current market capitalization of Amylyx Pharmaceuticals is $3.89B.
-
Who are Amylyx Pharmaceuticals’s competitors?
Alnylam Pharmaceuticals, Biohaven, Apellis Pharmaceuticals, Aquinnah, and Cognition Therapeutics are some of the 9 competitors of Amylyx Pharmaceuticals.
-
What is Amylyx Pharmaceuticals’s annual earnings per share (EPS)?
Amylyx Pharmaceuticals’s EPS for 12 months was -$1.45.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process